Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody–Associated Encephalopathy | Zendy

Sarosh R. Irani | Zendy; Jeffrey M. Gelfand | Zendy; Brianne M. Bettcher | Zendy; Neel S. Singhal | Zendy; Michael D. Geschwind | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody–Associated Encephalopathy

Author(s) -

Sarosh R. Irani,

Jeffrey M. Gelfand,

Brianne M. Bettcher,

Neel S. Singhal,

Michael D. Geschwind

Publication year - 2014

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2014.463

Subject(s) - rituximab , medicine , encephalopathy , population , modified rankin scale , antibody , immunology , gastroenterology , environmental health , ischemic stroke , ischemia

This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)-complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody-associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research